Key result
ECMO-assisted valve-in-valve TAVR restores LVEF by ~30 points in failed SAVR with Libman-Sacks endocarditis.
Why the study?
Libman-Sacks endocarditis associated with SLE and APS predisposes patients to thromboembolism and valvular dysfunction, and optimal anticoagulation and intervention strategies remain challenging, particularly in cases of rapid prosthetic failure.
Case Report (n=1)
No
This case report demonstrates the feasibility of ECMO-assisted valve-in-valve TAVR combined with warfarin anticoagulation and immunosuppression as a rescue strategy for rapid bioprosthetic SAVR failure in a patient with triple-positive APS and SLE-associated Libman-Sacks endocarditis.
Answers are grounded in this paper and cite their sources.
May support ECMO-assisted valve-in-valve TAVR rescue in APS/SLE endocarditis; hypothesis-generating and needs prospective validation.
Background Libman-Sacks endocarditis (LSE) is a non-infective valvular manifestation of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), affecting 15–30% of patients with APS. Characterized by sterile vegetations predisposing to thromboembolism and valvular dysfunction, optimal anticoagulation and intervention strategies remain challenging, particularly with rapid prosthetic failure. Case presentation A 63-year-old African American man with a 20-year history of SLE and triple-positive APS presented with cardiogenic shock five months after surgical aortic valve replacement (SAVR) for LSE. Echocardiography revealed severe bioprosthetic obstruction (mean gradient 79.6 mmHg, valve area 0.30 cm²). Given prohibitive redo surgical risk (STS-PROM 18.2%), he underwent ECMO-assisted valve-in-valve transcatheter aortic valve replacement (TAVR) with a 26 mm Edwards SAPIEN 3 valve. Left ventricular ejection fraction improved from 25-29% to 55-59% at 4.5 months, sustained at 50-54% at 8-month follow-up. He remained stable on warfarin (INR 2-3), hydroxychloroquine, and rituximab under multidisciplinary care. Discussion This case demonstrates diagnostic challenges differentiating LSE from bioprosthetic valve thrombosis (BPVT); a competing diagnosis that could not be excluded without histopathologic confirmation, critical limitations of DOACs in triple-positive APS, and feasibility of ECMO-supported TAVR as an exceptional rescue strategy. Rituximab was administered for refractory APS, though its independent contribution to the favorable outcome cannot be determined. Conclusion To our knowledge, this is the first reported ECMO-assisted valve-in-valve TAVR following SAVR failure in APS/SLE-associated LSE. It emphasizes multidisciplinary care, warfarin-based anticoagulation, immunosuppression escalation, and long-term surveillance for complex autoimmune valvular disease.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2026) conducted a case report in Severe bioprosthetic aortic valve obstruction and cardiogenic shock following SAVR for Libman-Sacks endocarditis in SLE and triple-positive APS (n=1). ECMO-assisted valve-in-valve transcatheter aortic valve replacement (TAVR) with a 26 mm Edwards SAPIEN 3 valve was evaluated on Left ventricular ejection fraction (LVEF) and clinical stability. ECMO-assisted valve-in-valve TAVR for failed SAVR in APS/SLE Libman-Sacks endocarditis improved LVEF from 25-29% to 55-59% at 4.5 months and 50-54% at 8 months.
Synapse has enriched 10 related papers. Consider them for comparative context: